Genotype analysis of the nrf2 gene mutation in lung cancer

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1135-1138

  Sasaki, Hidefumi ^a   Suzuki, Ayumi ^a   Shitara, Masayuki ^a   Hikosaka, Yu ^a   Okuda, Katsuhiro ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Mutation; NFE2L2; NRF2; Squamous Cell Carcinoma; Tumor Prognosis

Indexed keywords

TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SEX DIFFERENCE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID MOTIFS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NF-E2-RELATED FACTOR 2; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84876136899     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1324     Document Type: Article

References (32)

1. World Health Organization: Cancer. Fact Sheet 297. http://www.who.int/ mediacentre/factsheets/fs297/en/. Accessed February, 2012.
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
3. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
4. Soda H, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.
5. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384, 2012.
6. Kohno T, Ishikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012.
7. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS and ALK fusions in lung cancer. Nat Med 18: 378-381, 2012.
8. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell cancers. Nature 489: 519-525, 2012.
9. Itoh K, Chiba T, Takahashi S, et al: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
10. Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymes. Curr Drug Metab 3: 481-490, 2002.
11. Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37: 433-441, 2004.
12. Fahey JW and Kensler TW: Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Chem Res Toxicol 20: 572-576, 2007.
13. Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
14. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
15. Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology 55: 750-754, 2008.
16. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
17. Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol 5: 786-789, 2010.
18. Wittwer CT, Herrmann MG, Moss AA and Rasmussen RP: Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22: 130-138, 1997.
19. Pals G, Pindolia K and Worsham MJ: A rapid sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn 4: 241-246, 1999.
20. Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: Genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005.
21. Itoh K, Wakabayashi N, Katoh Y, et al: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
22. Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006.
23. Yokota K, Sasaki H, Okuda K, et al: KIF5B/RET fusion gene in surgically-treated Japanese adenocarcinoma of the lung. Oncol Rep 28: 1187-1192, 2012.
24. Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 39: 4743-4747, 2012.
25. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the Kras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001.
26. Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature 458: 719-724, 2009.
27. Muller T and Hengstermann A: Nrf2: Friend and foe in preventing cigarette smoking-dependent lung disease. Chem Res Toxicol 25: 1805-1824, 2012.
28. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
29. Zhou J, Scmid T, Schnitzer S and Brune B: Tumor hypoxia and cancer progression. Cancer Lett 237: 10-21, 2006.
30. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
31. Sasaki H, Shitara M, Yokota K, et al: MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas. Mol Med Rep 6: 705-708, 2012.
32. Leinonen HM, Ruotsalainen AK, Määttä AM, et al: Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Res 72: 6227-6235, 2012.